3-methylpicolinohydrazide | 958453-96-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-methylpicolinohydrazide
• 英文别名: 3-methyl-2-pyridinecarbohydrazide；3-Methylpyridine-2-carbohydrazide
• CAS: 958453-96-8
• 化学式: C₇H₉N₃O
• mdl: MFCD16710383
• 分子量: 151.168
• InChiKey: VQBNDWYVRSUPBG-UHFFFAOYSA-N

物化性质

• 密度：
  1.195±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  68
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-methylpicolinohydrazide 在 N-甲基吗啉 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 1.42h， 生成 (4-fluorophenyl)(3-(3-methylpyridin-2-yl)-5,6-dihydro-[1,2,4]-triazolo[4,3-a]pyrazin-7(8H)-yl)methanone
  参考文献：
  名称：

  Discovery and Optimization of Novel Antagonists to the Human Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part I)

  摘要：

  Neurokinin-3 receptor (NK3R) has recently emerged as important in modulating the tonic pulsatile gonadotropin-releasing hormone (GnRH) release. We therefore decided to explore NK3R antagonists as therapeutics for sex-hormone disorders that can potentially benefit from lowering GnRH pulsatility with consequent diminished levels of plasma luteinizing hormone (LH) and correspondingly attenuated levels of circulating androgens and estrogens. The discovery and lead optimization of a novel N-acyl-triazolopiperazine NK3R antagonist chemotype achieved through bioisosteric lead change from the high-throughput screening (HTS) hit is described. A concomitant improvement in the antagonist bioactivity and ligand lipophilic efficiency (LLE) parameter were the principal guidelines in the lead optimization efforts. Examples of advanced lead analogues to demonstrate the amenability of this chemotype to achieving a suitable pharmacokinetic (PK) profile are provided as well as pharmacokinetic-pharmacodynamic (PKPD) correlations to analyze the trends observed for LH inhibition in castrated rats and monkeys that served as preliminary in vivo efficacy models.

  DOI：

  10.1021/jm5017413
• 作为产物：
  描述：

  3-甲基吡啶-2-甲酸乙酯 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 42.25h， 生成 3-methylpicolinohydrazide
  参考文献：
  名称：

  [EN] 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS
  [FR] DÉRIVÉS DE 5,6,7,8-TÉTRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZINE COMME MODULATEURS DE P2X7

  摘要：

  本发明提供了一种式(I)化合物或其药学上可接受的盐，其中A为氢、C1-4烷基、C3-6环烷基、C1-3烷氧基、C1-3烷氧基C1-4烷基、C1-2氟烷基、卤素、NR6 R7、任选取代的杂芳基(Het)或任选取代的苯基，且R1、R2、R3、R4、R5、R6和R7如说明书中所定义。这些化合物或盐被认为能够调节P2X7受体功能，并能拮抗ATP在P2X7受体上的作用。本发明还提供了该化合物或盐在治疗或预防例如炎症性疼痛、神经性疼痛、内脏疼痛、类风湿性关节炎、骨关节炎或神经退行性疾病中的用途。

  公开号：

  WO2010125102A1

文献信息

• [EN] SUBSTITUTED NITROGEN CONTAINING COMPOUNDS<br/>[FR] COMPOSÉS CONTENANT DE L'AZOTE SUBSTITUÉ
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018222795A1

  公开（公告）日：2018-12-06

  Disclosed are compounds of Formula (I): or a salt thereof, Formula (II) wherein R1 is: or; each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

  揭示了以下式（I）的化合物或其盐，式（II）其中R1是：或；每个W独立地是NR1b或O；Z是键或CHR1d；以及R1、R2、Rd、R3a、R3b、L1、B、V、Y和n在此处被定义。还揭示了将这些化合物用作ROMK抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗心血管疾病方面是有用的。
• TRIAZOLE AGONISTS OF THE APJ RECEPTOR
  申请人：AMGEN INC.

  公开号：US20170037026A1

  公开（公告）日：2017-02-09

  Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

  公式I和公式II的化合物，其药学上可接受的盐，上述任何立体异构体，或其混合物是APJ受体激动剂，并可用于治疗心血管和其他疾病。公式I和公式II的化合物具有以下结构：其中变量的定义在此提供。
• 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS
  申请人：Dean David Kenneth

  公开号：US20120157436A1

  公开（公告）日：2012-06-21

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein A is hydrogen, C 1-4 alkyl, C 3-6 cycloalkyl, C 1-3 alkoxy, C 1-3 alkoxy C 1-4 alkyl, C 1-2 -fluoroalkyl, halogen, NR 6 R 7 , optionally substituted heteroaryl, or optionally substituted phenyl, and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis, osteoarthritis or neurodegenerative disorders.

  本发明提供了式（I）的化合物或其药学上可接受的盐： 其中，A为氢、C1-4烷基、C3-6环烷基、C1-3烷氧基、C1-3烷氧基C1-4烷基、C1-2氟代烷基、卤素、NR6R7、可选取代杂环芳基或可选取代苯基；R1、R2、R3、R4、R5、R6和R7如描述中所定义。 这些化合物或盐被认为可以调节P2X7受体功能，并能够拮抗P2X7受体上ATP的作用。本发明还提供了该化合物或盐在治疗或预防炎症性疼痛、神经病理性疼痛、内脏疼痛、类风湿性关节炎、骨关节炎或神经退行性疾病中的应用。
• 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators
  申请人：Dean David Kenneth

  公开号：US08501946B2

  公开（公告）日：2013-08-06

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein A is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy, C1-3alkoxy C1-4alkyl, C1-2fluoroalkyl, halogen, NR6R7, optionally substituted heteroaryl (Het), or optionally substituted phenyl, and R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis, osteoarthritis or neurodegenerative disorders.

  本发明提供了一个式（I）的化合物或其药学上可接受的盐：其中A为氢、C1-4烷基、C3-6环烷基、C1-3烷氧基、C1-3烷氧基C1-4烷基、C1-2氟代烷基、卤素、NR6R7、可选取代的杂环芳基（Het）或可选取代的苯基，而R1、R2、R3、R4、R5、R6和R7如描述中所定义。这些化合物或盐被认为可以调节P2X7受体功能，并且能够拮抗P2X7受体上ATP的作用。本发明还提供了该化合物或盐在治疗或预防例如炎症性疼痛、神经病理性疼痛、内脏疼痛、类风湿性关节炎、骨关节炎或神经退行性疾病中的用途。
• Tuning the photoluminescence properties of SLE- and MRL-active tricarbonylrhenium(I) complexes through minor structural changes of the organic ligand
  作者：Alexandre Poirot、Nadine Leygue、Béatrice Delavaux-Nicot、Nathalie Saffon-Merceron、Clémence Allain、Eric Benoist、Suzanne Fery-Forgues

  DOI：10.1016/j.jphotochem.2023.114982

  日期：2023.11

  parameters on the photoluminescence (PL) properties of tricarbonylrhenium(I) complexes, four molecules incorporating a 3-(2-pyridyl)-1,2,4-triazole (pyta) ligand with appended phenylbenzoxazole (PBO) unit were compared. One or two methyl groups were inserted at different places of the organic ligand of the parent compound RePBO, resulting in three new complexes RePBO-Me1, RePBO-Me2 and RePBO-Me3. As shown by

  固态发光特性取决于许多参数，包括分子几何形状和固体中发生的分子间相互作用。为了阐明这些参数对三羰基铼 (I) 配合物的光致发光 (PL) 性质所起的作用，对包含 3-(2-吡啶基)-1,2,4-三唑 (pyta) 配体和附加苯基苯并恶唑 (PBO) 单元的四种分子进行了比较。在母体化合物RePBO的有机配体的不同位置插入一或两个甲基，产生三种新的配合物RePBO-Me1、RePBO-Me2和RePBO-Me3。NMR显示，甲基的存在引起了分子柔性的一些变化，但电子效应相对较弱。结果，电化学和光学性质几乎没有受到影响，并且四种配合物在有机溶液中的表现几乎相似，与理论计算一致。相反，当考虑聚集诱导发射（AIE）效应时，复合物之间出现了显着差异，这主要是由于在水介质中形成了微小的微晶。同样，微晶粉末形式的三种甲基化配合物相对于溶液表现出明显的结晶诱导发射增强（CIEE），但具有明显的特征。与未取